BUZZ-Upstream Bio jumps as experimental asthma drug shows promise in mid‑stage study** Shares of drug developer Upstream Bio UPB.O rise 20% to $32.64 in premarket trading
** Company says its experimental asthma drug, Verekitug, reduced severe asthma attacks in a mid‑stage study
** The drug reduced yearly asthma flare‑ups by 56% at a lower dose and 39% at a higher dose, and improved lung function - UPB
** Side-effects were similar to earlier studies; over 90% of eligible patients entered a long‑term extension study, company says
** UPB plans late‑stage trials in severe asthma and chronic sinus disease after talks with regulators
** Shares up ~65% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.